Engineers at a deeptech company collaborate on a project in their cluttered lab.
New Delhi, India – Deeptech company SEDEMAC has announced a robust financial performance for the fourth quarter of fiscal year 2026, with net profit surging 273% year-on-year to ₹32.1 Cr. The company’s operating revenue also saw significant growth, climbing 60% YoY to ₹287.7 Cr, driven primarily by demand in the mobility sector.
SEDEMAC’s strong Q4 results were bolstered by a widening product footprint and increased operational scale, which led to an improvement in EBITDA margins to 21.3% from 16.1% in the prior year’s comparable quarter. The mobility division accounted for nearly 90% of the company’s revenue, with annual electronic control unit (ECU) sales reaching 39 Lakh units in FY26, a 63% increase year-on-year.
Looking ahead, SEDEMAC is preparing for expansion with new products for commercial vehicles and electric light commercial vehicles. The company is also investing in new manufacturing facilities in Pune and Tamil Nadu to support future growth and customer demand in South India.
In parallel, biotech startup Cellogen Therapeutics has successfully raised approximately $2 million in a seed funding round led by Kotak Alternate Asset Managers. The funds will be utilized to advance its clinical programs, expand its gene therapy pipeline, and enhance its manufacturing and regulatory capabilities.
Founded in 2021, Cellogen Therapeutics focuses on developing cellular engineering therapies for cancers and blood disorders, aiming to offer treatments at a significantly lower cost than current market prices. The company is collaborating with CMC Vellore for its Phase I human clinical trials and has previously secured a patent for its CAR-T platform.
These developments highlight active capital deployment and significant operational milestones within India’s technology and biotechnology sectors.
About the Author
